Slipped capital femoral epiphyses: A major on-target adverse event associated with FGFR tyrosine kinase inhibitors in pediatric patients.
Sameer Farouk SaitCheryl FischerZoltan AntalKrisoula SpatzDaniel E PrinceKatarzyna IbanezGerald G BehrIra J DunkelMatthias A KarajannisPublished in: Pediatric blood & cancer (2023)
Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors (TKIs) are increasingly being used off label in pediatrics. Long-term safety data are limited, and serious toxicities unique to pediatrics may emerge. In a retrospective analysis of patients less than 18 years of age with recurrent/refractory FGFR altered gliomas treated with FGFR TKIs at MSKCC (n = 7), we observed slipped capital femoral epiphyses in three of seven patients along with increased linear growth velocity. Clinicians should closely monitor bone health and have a low index of suspicion for serious orthopedic complications including slipped capital femoral epiphyses and inform patients of related risks as part of consent when treating with FGFR TKIs.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- healthcare
- prognostic factors
- public health
- peritoneal dialysis
- climate change
- palliative care
- machine learning
- electronic health record
- risk assessment
- health information
- bone mineral density
- big data
- deep learning
- postmenopausal women
- bone regeneration